167 related articles for article (PubMed ID: 36942924)
21. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
22. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
23. Head-to-Head Comparison of [
Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
[TBL] [Abstract][Full Text] [Related]
24. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
25. High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors.
Wang Y; Yuan H; Liu N; Tang S; Feng Y; Liu Y; Cai P; Xia L; Zheng W; Chen Y; Zhou Z
J Med Chem; 2023 Jul; 66(13):8614-8627. PubMed ID: 37390480
[TBL] [Abstract][Full Text] [Related]
26. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
28. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-α
Yan Q; Zhong J; Liu Y; Peng S; Feng P; Zhong Y; Hu K
Eur J Med Chem; 2023 May; 251():115279. PubMed ID: 36931125
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Preliminary Study of
Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Evaluation of
Bendre S; Zhang Z; Colpo N; Zeisler J; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110717
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
33. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature.
Eder M; Krivoshein AV; Backer M; Backer JM; Haberkorn U; Eisenhut M
Nucl Med Biol; 2010 May; 37(4):405-12. PubMed ID: 20447550
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
Moon ES; Van Rymenant Y; Battan S; De Loose J; Bracke A; Van der Veken P; De Meester I; Rösch F
Molecules; 2021 Jun; 26(12):. PubMed ID: 34201111
[TBL] [Abstract][Full Text] [Related]
35. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
36. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Ding J; Xu M; Chen J; Zhang P; Huo L; Kong Z; Liu Z
Mol Pharm; 2022 Sep; 19(9):3429-3438. PubMed ID: 35976352
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.
Wang P; Wang S; Liu F; Ren Y; Guo Q; Zhang Q; Hou X; Yao Y; Zhu H; Yang Z
Mol Pharm; 2023 Feb; 20(2):1415-1425. PubMed ID: 36697367
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
39. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
[TBL] [Abstract][Full Text] [Related]
40. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
